Trends in all cause and viral liver disease-related hospitalizations in people with hepatitis B or C: a population-based linkage study

被引:12
作者
Gidding, Heather F. [1 ]
Dore, Gregory J. [1 ]
Amin, Janaki [1 ]
Law, Matthew G. [1 ]
机构
[1] Univ New S Wales, Natl Ctr HIV Epidemiol & Clin Res, Sydney, NSW, Australia
关键词
TENOFOVIR DISOPROXIL FUMARATE; COMMUNITY-BASED LINKAGE; NEW-SOUTH-WALES; VIRUS-INFECTION; HEPATOCELLULAR-CARCINOMA; FIBROSIS PROGRESSION; RECORD-LINKAGE; UNITED-STATES; ANTIRETROVIRAL-THERAPY; ADEFOVIR DIPIVOXIL;
D O I
10.1186/1471-2458-11-52
中图分类号
R1 [预防医学、卫生学];
学科分类号
100235 [预防医学];
摘要
Background: Previous studies have reported an excess burden of cancer and mortality in populations with chronic hepatitis B (HBV) or C (HCV), but there are limited data comparing hospitalization rates. In this study, we compared hospitalization rates for all causes and viral liver disease in people notified with HBV or HCV in New South Wales (NSW), Australia. Methods: HBV and HCV notifications were linked to their hospital (July 2000-June 2006), HIV and death records. Standardized hospitalization ratios (SHRs) were calculated using rates for the NSW population. Random effects Poisson regression was used to examine temporal trends. Results: The SHR for all causes and non alcoholic liver disease was two-fold higher in the HCV cohort compared with the HBV cohort (SHRs 1.4 (95% CI: 1.4-1.4) v 0.6 (95% CI: 0.6-0.6) and 14.0 (95% CI: 12.7-15.4) v 5.4 (95% CI: 4.5-6.4), respectively), whilst the opposite was seen for primary liver cancer (SHRs 16.2 (95% CI: 13.8-19.1) v 29.1 (95% CI: 24.7-34.2)). HIV co-infection doubled the SHR except for primary liver cancer in the HCV/HIV cohort. In HBV and HCV mono-infected cohorts, all cause hospitalization rates declined and primary liver cancer rates increased, whilst rates for non alcoholic liver disease increased by 9% in the HCV cohort but decreased by 14% in the HBV cohort (P < 0.001). Conclusion: Hospital-related morbidity overall and for non alcoholic liver disease was considerably higher for HCV than HBV. Improved treatment of advanced HBV-related liver disease may explain why HBV liver-related morbidity declined. In contrast, HCV liver-related morbidity increased and improved treatments, especially for advanced liver disease, and higher levels of treatment uptake are required to reverse this trend.
引用
收藏
页数:9
相关论文
共 49 条
[1]
Alam N., 2009, LIVER CANC NEW S WAL
[2]
Liver cancer and hepatitis B and C in New South Wales, 1990-2002: a linkage study [J].
Amin, Janaki ;
O'Connell, Dianne ;
Bartlett, Mark ;
Tracey, Elizabeth ;
Kaldor, John ;
Law, Matthew ;
Dore, Gregory .
AUSTRALIAN AND NEW ZEALAND JOURNAL OF PUBLIC HEALTH, 2007, 31 (05) :475-482
[3]
Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study [J].
Amin, Janaki ;
Law, Matthew G. ;
Bartlett, Mark ;
Kaldor, John M. ;
Dore, Gregory J. .
LANCET, 2006, 368 (9539) :938-945
[4]
Cancer incidence in people with hepatitis B or C infection: A large community-based linkage study [J].
Amin, Janaki ;
Dore, Gregory J. ;
O'Connell, Dianne L. ;
Bartlett, Mark ;
Tracey, Elizabeth ;
Kaldor, John M. ;
Law, Matthew G. .
JOURNAL OF HEPATOLOGY, 2006, 45 (02) :197-203
[5]
Benhamou Y, 1999, HEPATOLOGY, V30, p362A
[6]
Blum Hubert E, 2002, J Gastroenterol Hepatol, V17 Suppl 3, pS413, DOI 10.1046/j.1440-1746.17.s3.37.x
[7]
THE EFFECT OF CONCURRENT HUMAN IMMUNODEFICIENCY VIRUS-INFECTION ON CHRONIC HEPATITIS-B - A STUDY OF 150 HOMOSEXUAL MEN [J].
BODSWORTH, N ;
DONOVAN, B ;
NIGHTINGALE, BN .
JOURNAL OF INFECTIOUS DISEASES, 1989, 160 (04) :577-582
[8]
Long-Term Entecavir Therapy Results in the Reversal of Fibrosis/Cirrhosis and Continued Histological Improvement in Patients with Chronic Hepatitis B [J].
Chang, Ting-Tsung ;
Liaw, Yun-Fan ;
Wu, Shun-Sheng ;
Schiff, Eugene ;
Han, Kwang-Hyub ;
Lai, Ching-Lung ;
Safadi, Rifaat ;
Lee, Samuel S. ;
Halota, Waldemar ;
Goodman, Zachary ;
Chi, Yun-Chan ;
Zhang, Hui ;
Hindes, Robert ;
Iloeje, Uchenna ;
Beebe, Suzanne ;
Kreter, Bruce .
HEPATOLOGY, 2010, 52 (03) :886-893
[9]
Entecavir Treatment for up to 5 Years in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B [J].
Chang, Ting-Tsung ;
Lai, Ching-Lung ;
Yoon, Seung Kew ;
Lee, Samuel S. ;
Coelho, Henrique Sergio M. ;
Carrilho, Flair Jose ;
Poordad, Fred ;
Halota, Waldemar ;
Horsmans, Yves ;
Tsai, Naoky ;
Zhang, Hui ;
Tenney, Daniel J. ;
Tamez, Ricardo ;
Iloeje, Uchenna .
HEPATOLOGY, 2010, 51 (02) :422-430
[10]
EFFICACY AND SAFETY OF PEGINTERFERON ALFA-2A 360 μG/WEEK IN COMBINATION WITH RIBAVIRIN IN HEPATITIS C GENOTYPE I PATIENTS WITH CIRRHOSIS: ANALYSIS FROM THE CHARIOT STUDY [J].
Cheng, W. S. C. ;
Roberts, S. ;
Weltman, M. ;
Crawford, D. H. G. ;
Sievert, W. ;
McCaughan, G. ;
Rawlinson, W. ;
Desmond, P. ;
Yoshihara, M. ;
Rizkalla, B. ;
DePamphilis, J. ;
Marks, P. ;
Dore, G. J. .
JOURNAL OF HEPATOLOGY, 2009, 50 :S221-S221